Pre-Stem Cell Transplant Treatment Regimen for AML, MDS - NCI

Pre-Stem Cell Transplant Treatment Regimen for AML, MDS - NCI

A Cancer Currents blog on a study suggesting that an intensive preparatory regimen should be used for younger patients with AML undergoing a stem cell transplant.

Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia - ScienceDirect

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation

JCM, Free Full-Text

Pediatric Allogeneic HSCT (PDQ®) - NCI

A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies

Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation

Cancers, Free Full-Text

Acute myeloid leukaemia - The Lancet

Myelodysplastic syndrome - Wikipedia

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)

Frontiers Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML